Wall Street analysts expect that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will report earnings of ($0.39) per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.35) and the lowest estimate coming in at ($0.41). The company is expected to announce its next quarterly earnings report on Wednesday, June 12th.

On average, analysts expect that Crinetics Pharmaceuticals will report full year earnings of ($1.89) per share for the current year, with EPS estimates ranging from ($2.38) to ($1.61). For the next fiscal year, analysts expect that the business will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.55) to ($2.02). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Wednesday, March 13th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.06. Crinetics Pharmaceuticals had a negative net margin of 1,117.52% and a negative return on equity of 38.38%. The firm had revenue of $0.78 million for the quarter, compared to analyst estimates of $0.32 million.

Several research firms have recently commented on CRNX. Cantor Fitzgerald began coverage on shares of Crinetics Pharmaceuticals in a research report on Monday, March 11th. They issued an “overweight” rating and a $40.00 target price for the company. HC Wainwright began coverage on shares of Crinetics Pharmaceuticals in a research report on Thursday, February 14th. They issued a “buy” rating and a $35.00 target price for the company. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $37.20.

Shares of Crinetics Pharmaceuticals stock opened at $23.79 on Friday. The firm has a market capitalization of $573.22 million and a PE ratio of -10.67. Crinetics Pharmaceuticals has a 52-week low of $19.23 and a 52-week high of $42.00.

In related news, major shareholder Vivo Capital Fund Viii, L.P. sold 417,000 shares of the stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $22.25, for a total value of $9,278,250.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Ventures Iv L.P. 5Am sold 262,153 shares of the stock in a transaction dated Tuesday, January 22nd. The stock was sold at an average price of $21.88, for a total transaction of $5,735,907.64. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 833,992 shares of company stock valued at $18,769,003.

Institutional investors have recently modified their holdings of the stock. Rhumbline Advisers bought a new position in shares of Crinetics Pharmaceuticals in the 4th quarter worth about $254,000. TIAA CREF Investment Management LLC bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $268,000. Vanguard Group Inc. bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $7,103,000. Bank of New York Mellon Corp bought a new position in shares of Crinetics Pharmaceuticals in the 3rd quarter worth about $453,000. Finally, Emory University bought a new position in shares of Crinetics Pharmaceuticals in the 4th quarter worth about $2,577,000. Institutional investors own 69.68% of the company’s stock.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Further Reading: What are convertible shares? 

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.